Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to China's clinical trials of COVID-19 treatment, the number of chemical drugs accounted for the highest proportion, followed by biological drugs, cell therapy, vaccines, and traditional Chinese medicine. Among the biological drugs, IL-6 related monoclonal antibodies (anti-inflammatory) account for the largest proportion, including tocilizumab and Sarilumab. This report focuses on the investigation and analysis of biologic medication and predicts the future market development of biopharmaceuticals under the influence of COVID-19. Biological drugs are mainly divided into two categories: neutralizing antibodies and anti-inflammatory drugs. The main subdivisions include: IL-6, C5a, CD147, PD-1 and Interferon (beta-1a), etc.
Market Analysis and Insights: Global Biologic Medication in COVID-19 Market
In 2021, the global Biologic Medication in COVID-19 market size will be US$ million and it is expected to reach US$ million by the end of 2027, with a CAGR of % during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biologic Medication in COVID-19 market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biologic Medication in COVID-19 market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biologic Medication in COVID-19 market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biologic Medication in COVID-19 market.
Global Biologic Medication in COVID-19 Scope and Market Size
Biologic Medication in COVID-19 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biologic Medication in COVID-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Market Analysis and Insights: Global Biologic Medication in COVID-19 Market
In 2021, the global Biologic Medication in COVID-19 market size will be US$ million and it is expected to reach US$ million by the end of 2027, with a CAGR of % during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biologic Medication in COVID-19 market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biologic Medication in COVID-19 market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biologic Medication in COVID-19 market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biologic Medication in COVID-19 market.
Global Biologic Medication in COVID-19 Scope and Market Size
Biologic Medication in COVID-19 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biologic Medication in COVID-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segment by Application
COVID-19
Influenza
Malaria
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
